MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed an Exclusive Distribution Agreement with EMC LABS, S.A.P.I. DE C.V., operating as MedX Mexico (“MedX Mexico”), which plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX’s SIAscopy on DermSecure™ Telemedicine platform. The exclusivity was granted to MedX Mexico based on its strong connections within the Mexican marketplace as well as its upfront commitment to cover the application for regulatory approval in Mexico and all marketing costs, and the large-scale distribution network it has secured. The agreement also has a robust performance clause that reflects the strong commitment by MedX Mexico and the opportunity in the Mexican market.
“There is a significant opportunity for MedX’s rapid skin assessment technology in Mexico, as skin cancer is a very common type of cancer in Mexico,” stated Carlos Vizcaino, MedX Mexico’s, President and CEO. “A recent study shows that Mexican melanoma patients experience a lower survival rate than the current worldwide average. This fact is based on two factors, namely late stage diagnosis due to the lack of early screening and the ill-informed belief that our community is not as susceptible as others to skin cancer. The high prevalence of advanced cases reinforces the importance of local strategies to diagnose melanoma in the early stages, to treat it definitively and to be able to reach many underserved communities. MedX’s SIAscopy on DermSecure™Telemedicine platform and advanced SIAscopy imaging technology is a perfect solution to assist dermatologists and physicians in the diagnosis process for early detection of melanoma,” further noted Mr. Vizcaino.
“MedX Mexico has experience in marketing medical devices and health solutions in the Mexican market, as well as a strong connections with hospitals, major pharmacies and medical clinics which will be a great benefit as it enters into this large market, and we are delighted to be partnering with them,” noted Scott Spearn, President & CEO of MedX.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, Brazil, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
About EMC LABS, S.A.P.I. DE C.V. operating as MedX Mexico
The founders of MedX Mexico form a partnership that brings decades of professional business development, strategy, manufacturing, training, logistics, regulatory compliance and medical device distribution experience. The business relationships already established in Mexico are extensive and cover hospitals, medical clinics, pharmacies, regulatory agencies, government departments and private industry. These relationships provide a synergy between Mexico and Canada that will ensure expedited market entry for this life saving solution.
The founders understand the importance of Mexico as the second largest importer of medical devices in the Latin America market, just behind Brazil. Their relationship with MedX Health Corp. and its rapid skin assessment solution, combined with their corporate and business experience, will give MedX Mexico the opportunity to open the Mexican marketplace rapidly, and will place it in a strong position to reduce the mortality rate currently being experienced owing to the late detection of skin cancer.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.